-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anti-tumor necrosis factor (anti-TNF) drugs damage the protective immunity of pneumococcal, influenza and viral hepatitis vaccines , increasing the risk of severe respiratory infections .
Immune infection
They compared the antibody response of participants receiving infliximab with a reference group receiving vedolizumab.
Forest plot showing the correlation coefficient of the multivariate logistic regression model with anti- SARS-CoV-2 antibody positive
Forest diagram shows the anti- SARS-CoV-2 multi-variable antibody positive logistic regression correlation coefficient forest illustration shows the anti- SARS-CoV-2 multi-variable antibody positive logistic regression correlation coefficientA hierarchical density map of the size of the anti- SARS-CoV-2 antibody reactivity through biological therapy .
A hierarchical density map of the size of the anti- SARS-CoV-2 antibody reactivity through biological therapy .
The study found that symptomatic and confirmed SARS-CoV-2 infection rates and hospitalization rates were similar between patients treated with infliximab and vedoliximab, indicating that our findings cannot be based on acquired or severe infections.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
Patients receiving infliximab treatment have a reduced serological response to SARS-CoV-2 SARS-CoV-2 infection, and reduced seropositivity, seroconversion rate, and antibody reactivity in patients receiving infliximab treatment .
Kennedy, Nicholas A et al.
Kennedy, Nicholas A et al.
Leave a message here